DEFC14A: Opus Genetics Faces Proxy Battle as Sooch Group Challenges Board at Upcoming Annual Meeting

Opus Genetics is urging shareholders to vote for its director nominees amidst a proxy fight initiated by a stockholder group led by former CEO Mina Sooch.

Summary

• Opus Genetics is holding its 2025 annual meeting on April 30, 2025, and is soliciting proxies from its stockholders.
• The agenda includes the election of nine directors, ratification of Ernst & Young as the independent accounting firm, approval of executive compensation, approval of the conversion of Series A Preferred Stock into common stock, and approval of potential meeting adjournments.
• A stockholder group led by former CEO Mina Sooch is nominating six candidates for election to the board, leading to a contested election.
• The board recommends voting for its nine nominees using the BLUE proxy card and disregarding any materials from the Sooch Group.
• The company has engaged Sodali & Co. for proxy solicitation services at a cost of up to $300,000, plus expenses.
• The company estimates its expenses in connection with the proxy solicitation to be approximately $1,200,000, of which approximately $800,000 has been incurred as of the date of this proxy statement.
• The company has been engaging with stockholders, meeting with approximately 15 of its 20 largest investors representing approximately 25% of the outstanding shares of Common Stock as of December 31, 2024.

Sentiment

Score: 4

Explanation: The document is largely neutral, presenting facts about the upcoming annual meeting and the proxy contest. The conflict with the Sooch Group introduces a negative element, but the overall tone is professional and informative.

Positives

• The board has nominated a slate of nine directors with diverse skills and experiences relevant to the company's business and strategic objectives.
• The company has a commitment to ongoing stockholder engagement and values stockholder feedback.
• The company has enhanced stockholder rights by amending its bylaws to eliminate procedural requirements for stockholders to act by written consent, providing holders of 20% of the issued and outstanding shares the ability to call a special meeting of the company's stockholders, reducing the existing threshold for stockholders to remove directors (with or without cause) from 66 2/3% to a simple majority of the outstanding shares, providing stockholders with the exclusive authority to amend certain provisions of the A&R Bylaws; and reducing the threshold for stockholders to amend the A&R Bylaws from 66 2/3% to a simple majority of the outstanding shares.

Negatives

• The company is engaged in a costly and disruptive proxy contest with a stockholder group led by its former CEO.
• The company's say-on-pay proposal received significantly less support at the 2024 annual meeting compared to the previous year, indicating potential stockholder dissatisfaction with executive compensation practices.
• The potential change in control resulting from the proxy contest could trigger certain provisions in the company's material agreements and other legal instruments, potentially leading to accelerated vesting of equity awards and enhanced severance benefits for certain officers and employees.

Risks

• The outcome of the proxy contest is uncertain and could result in a change in control of the company.
• The conversion of Series A Preferred Stock into common stock could dilute existing stockholders' ownership and depress the market price of the common stock.
• Failure to obtain stockholder approval for the conversion of Series A Preferred Stock could result in additional costs and management distraction.
• The company's reliance on Viatris for the commercialization of Ryzumvi carries risks related to regulatory approvals, market acceptance, and Viatris's willingness to continue development and commercialization efforts.

Future Outlook

The company intends to use the net proceeds from the Offering for general corporate purposes and working capital, including for preclinical studies and clinical trials and the advancement of our product candidates.

Management Comments

• In a letter presented to the Ocuphire Board (the April 19 Letter) she stated, among other things, that the directors of Ocuphire are all here because of me.
• On April 21, 2023, Ms. Sooch made a number of public statements to Eyewire+, an online media ophthalmology website, regarding her termination: Im evaluating my options As you know, Ive built [Ocuphire] and I want it to be a successful company in the future. I need to have confidence in this management team and this plan in order for me to go quietly in the night.
• She continued, There are no milestones in the next two years I am not capable of executing on. The ship I built is solid.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors beyond the general context of a proxy contest and corporate governance matters.

Corporate Governance

Related Party Transactions

• On October 22, 2024, the Company completed an acquisition (the Acquisition) of Opus Genetics Inc. (Legacy Opus), pursuant to that certain Agreement and Plan of Merger (the Merger Agreement), dated as of October 22, 2024 (the Closing Date), by and among the Company, Orange Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Company, Orange Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company, and Legacy Opus.
• Under the terms of the Merger Agreement, at the closing of the Acquisition, the Company issued to the securityholders of Legacy Opus 5,237,063 shares of Common Stock and 14,145.374 shares of the Companys preferred stock, par value $0.0001 per share, designated as Series A Preferred (the Series A Preferred Stock).
• In connection with the Acquisition and effective October 22, 2024, Dr. Benjamin R. Yerxa, the former Chief Executive Officer and President of Legacy Opus and the former Chief Executive Officer of FFB, entered into an employment agreement (the Yerxa Employment Agreement) with the Company.
• In connection with Dr. Jean Bennetts appointment as a member of the Board, effective October 22, 2024, she and the Company entered into a consulting agreement (the Bennett Consulting Agreement), pursuant to which Dr. Bennett will provide consulting services to the Company for a one-year period.
• On August 25, 2022, Legacy Opus entered into a binding letter of agreement with FFB and the Jaeb Center for Health Research (JCHR) to collaborate on natural history studies involving individuals with retinal dystrophies associated with mutations in multiple genes of interest.

Stakeholder Impact

• The outcome of the proxy contest will directly impact the composition of the board of directors and, consequently, the strategic direction of the company, affecting shareholders, employees, and other stakeholders.
• The potential conversion of Series A Preferred Stock into common stock will dilute existing shareholders' ownership.
• The company's performance and strategic decisions will impact the value of shareholders' investments.
• The company's ability to execute its business plan and develop new therapies will impact patients and the broader healthcare community.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will hold its annual meeting on April 30, 2025.
• The company will continue to engage with stockholders and solicit proxies in support of its board nominees and proposals.

Key Dates

Keywords

proxy solicitation, annual meeting, director election, corporate governance, executive compensation, Mina Sooch, Opus Genetics, Series A Preferred Stock, stockholder vote